Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q2 2023 · 10-Q
Revenue$146.92M$146.92M+17.5% vs Q2 2022 Net Income-$24.33M-$24.33MN/M vs Q2 2022 EPS Diluted-$0.19-$0.19N/M vs Q2 2022 Gross Profit$59,891,000+36.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,548,000N/M Free Cash Flowderived-$9,042,000N/M Margins · derivedGross margin40.8%+5.6 pt vs Q2 2022
Operating margin-20.3%+11.4 pt vs Q2 2022
Net margin-16.6%+11.7 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 8, 2023 · 39 d after period end